C83.30

Diffuse large B-cell lymphoma, unspecified site

## Introduction Diffuse Large B-Cell Lymphoma (DLBCL) is a highly aggressive and heterogeneous malignancy arising from mature B-lymphocytes. It is the most common subtype of non-Hodgkin lymphoma (NHL) globally, accounting for approximately 30% to 40% of all newly diagnosed lymphoma cases. DLBCL is characterized by its rapid clinical course and large neoplastic cells that infiltrate and efface the normal architecture of lymph nodes or extranodal tissues. The ICD-10-CM code C83.30 refers to DLBCL when the specific site of involvement is not documented, or when the malignancy is present in multiple sites without a single predominant focus identified in clinical records. ## Pathophysiology and Molecular Subtyping DLBCL originates from germinal center or post-germinal center B-cells. Molecular profiling using gene expression profiling (GEP) has identified two distinct cell-of-origin (COO) subtypes: Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC). The GCB subtype typically originates from light-zone germinal center B-cells and is associated with chromosomal translocations such as t(14;18). The ABC subtype, which has a poorer prognosis, is characterized by constitutive activation of the NF-ΙB pathway. Furthermore, "double-hit" or "triple-hit" lymphomas are specific high-grade subtypes involving rearrangements of MYC and BCL2 and/or BCL6, requiring intensive therapeutic strategies due to their resistance to standard treatments. ## Clinical Presentation Patients typically present with a rapidly enlarging, painless mass, most often a lymph node in the neck, groin, or abdomen. However, approximately 40% of cases are primarily extranodal, involving sites such as the gastrointestinal tract, central nervous system, skin, and bone. Systemic symptoms, known as "B-symptoms," including unexplained fever (>38C), drenching night sweats, and significant weight loss (>10% of body weight in 6 months), occur in about one-third of patients. Localized symptoms may include abdominal pain, bowel obstruction, or focal neurological deficits depending on the organ systems involved. ## Diagnostic Criteria and Staging A definitive diagnosis requires an excisional tissue biopsy; fine-needle aspiration is generally inadequate for subtyping and architectural assessment. Immunohistochemistry (IHC) is used to confirm the B-cell lineage (CD19, CD20, CD79a) and to determine the COO using algorithms like the Hans criteria (CD10, BCL6, MUM1). Staging is primarily conducted via PET/CT scan to assess the metabolic activity and extent of the disease using the Lugano classification (Stage I-IV). Laboratory evaluation includes lactate dehydrogenase (LDH), which serves as a surrogate marker for tumor burden and a key component of the International Prognostic Index (IPI). ## Management and Standard of Care The standard frontline therapy for DLBCL is the R-CHOP regimen, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. While aggressive, DLBCL is considered highly curable, with roughly 60% of patients achieving long-term remission after initial therapy. For patients who are refractory to or relapse after first-line treatment, options include salvage chemotherapy followed by autologous stem cell transplantation (ASCT) or advanced immunotherapies such as Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific antibodies.

Clinical Symptoms

  • Rapidly enlarging painless lymphadenopathy
  • Unexplained fever (>38C)
  • Drenching night sweats
  • Unintentional weight loss (>10% in 6 months)
  • Severe fatigue and malaise
  • Abdominal pain or bloating
  • Chest pain or cough (mediastinal involvement)
  • Early satiety
  • Pruritus (itching)

Common Causes

  • Genetic mutations (MYC, BCL2, BCL6 translocations)
  • Advanced age (median age at diagnosis is 66)
  • Immunosuppression (HIV/AIDS, post-transplant)
  • Autoimmune disorders (e.g., Sj’gren's syndrome, Rheumatoid Arthritis)
  • Previous exposure to chemotherapy or radiation
  • History of lower-grade lymphomas (e.g., follicular lymphoma transformation)
  • Infection with Epstein-Barr Virus (EBV) in specific subsets

Documentation & Coding Tips

Transition from Unspecified Site to Specific Site Codes

Example: Patient with Stage III Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell (GCB) subtype, involving the axillary and inguinal lymph nodes bilaterally. Coding should shift from C83.30 to C83.38 (multiple sites) or the specific anatomical location to reflect systemic involvement and medical necessity for multi-agent chemotherapy. Billing Focus: Bilateral involvement of specific nodal regions. Risk Adjustment: HCC 12 (Breast and Other Cancers) capturing severity of systemic malignancy.

Billing Focus: Identify anatomical location to replace C83.30 with specific codes C83.31-C83.39.

Document Cell of Origin and Molecular Subtype

Example: Diagnosis: DLBCL, Activated B-cell (ABC) subtype, MYC and BCL2 rearranged (Double-hit lymphoma). Clinical status: Refractory to R-CHOP, currently planning for CAR-T therapy. Billing Focus: Identification of 'High-grade B-cell lymphoma' (C85.80) if molecular features override standard DLBCL classification. Risk Adjustment: Reflects significantly higher disease severity and poor prognostic outlook in the risk profile.

Billing Focus: Molecular markers like MYC, BCL2, and BCL6 rearrangements.

Specify the IPI (International Prognostic Index) Factors

Example: Diffuse large B-cell lymphoma, unspecified site. IPI Score: 4 (High risk) based on: Age 65, LDH > normal (450 U/L), ECOG Performance Status 2, and 2 extranodal sites (bone and liver). Billing Focus: Inclusion of LDH levels and Performance Status in the narrative to support medical necessity for inpatient vs outpatient care. Risk Adjustment: ECOG status links to functional decline (Z74.01), further refining the risk score.

Billing Focus: Serum LDH levels and performance status (ECOG or Karnofsky).

Distinguish Primary vs. Secondary CNS Involvement

Example: Diffuse large B-cell lymphoma involving unspecified sites, now presenting with secondary CNS involvement (leptomeningeal spread). Billing Focus: Use C83.30 in conjunction with C79.32 (Secondary malignant neoplasm of cerebral meninges) to capture the complication. Risk Adjustment: CNS involvement significantly elevates the severity index and resource allocation for intrathecal therapy.

Billing Focus: Secondary site coding for metastatic or extra-nodal spread.

Clarify Current Treatment Status and Encounter Type

Example: Encounter for management of DLBCL, unspecified site. Patient is mid-cycle for R-EPOCH chemotherapy. No evidence of tumor lysis syndrome today. Billing Focus: Use Z51.11 as primary code for chemotherapy encounters, with C83.30 as secondary. Risk Adjustment: Active treatment status indicates an active malignancy (vs history of), maintaining HCC 12 eligibility.

Billing Focus: Z51.11 (Chemotherapy) vs Z08 (Follow-up after treatment).

Relevant CPT Codes

Related Diagnoses

Hierarchy